Indaptus Therapeutics, Inc. (INDP)

Market Cap	379.74M +8,415.7%
Revenue (ttm)	n/a
Net Income	-15.42M
EPS	-0.47
Shares Out	133.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,326,901
Open	2.250
Previous Close	2.210
Day's Range	2.250 - 2.890
52-Week Range	0.920 - 5.960
Beta	0.97
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 11, 2026

About INDP

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 5
• Stock Exchange: Nasdaq
• Ticker Symbol: INDP
• Website: https://indaptusrx.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error